Tetra-Antimony(III)-Bridged 18-Tungsto-2-Arsenates(V), [(LSb(III))4(A-α-As(V)W9O34)2](10-) (L = Ph, OH): Turning Bioactivity On and Off by Ligand Substitution

Discrete Molecular Aggregates Based on ZnII and SbIII/V Ions Displaying Efficient Antibacterial and Antioxidant Properties

The reactions of [Zn₃Cl₂(3,5-Me₂PzH)₄(t-BuPO₃)₂] with organostibonic acid in varying reaction conditions have been investigated. Single-crystal X-ray diffraction studies reveal the formation of [Zn₂(p-ClC₆H₄Sb)₂(O)₂(OCH₃)₂(t-BuPO₃)₃(py)₂] (1), [Zn₂(p-ClC₆H₄Sb^V)₄(Sb^III)₂(O)₈(t-BuPO₃H)₄(t-BuPO₃)₂(py)₂Cl₂] (2), and [Zn₂(RSb)₄(O)₄(OCH₃)₄(t-BuPO₃)₄(py)₂], where R = p-ClC₆H₄ (3) and R = p-iPrC₆H₄ (4), respectively. Interestingly, in the synthesis of 2, complete dearylation of organoantimony moieties followed by C-F bond formation, a reduction from Sb (V) to Sb (III), and Sb···Cl weak intermolecular interactions have been observed. ESI-MS studies suggested that clusters 1-4 maintained their structural integrity in the solution state also. Solution NMR studies (¹H, ³¹P, and ¹³C) support well the observed solid-state structures. 1-4 were tested for antibacterial activity using a microdilution assay. 1 and 4 showed the best activity with lower MIC values (0.78-6.25 μg/mL) against all the tested pathogens. The total antioxidant activity of 1-4 was evaluated through the phosphomolybdenum assay, which showed a total antioxidant activity ranging from 28.96 to 86.46 mg AAE/g compound with the ascorbic acid standard.

Revisiting the Three Vanadium Sandwich-Type Polyoxometalates: Structures, Solution Behavior, and Redox Properties

It is well known that the trivacant anions α-B-[XW₉O₃₃]^9- react with vanadyl ions to give the sandwich-type polyoxometalates [(V^IVO)₃(XW₉O₃₃)₂]^12- with X = As^III or Sb^III. Nevertheless, the oxidized derivatives have been obtained selectively by electrochemical oxidation from the fully reduced derivatives [(V^IVO)₃(XW₉O₃₃)₂]^12- allowing full characterization both in solution using UV-vis and multinuclear (¹⁷O, ⁵¹V, and ¹⁸³W) NMR spectroscopies and in the solid state by single-crystal X-ray diffraction. Structural analysis of the oxidized [(V^VO)₃(XW₉O₃₃)₂]^9- polyanions is consistent with the idealized D_3h symmetry, while solution studies reveal a fair hydrolytic stability in a wide pH range from 0 to 6. Besides, the D_3h polyanions either as reduced or oxidized forms [(VO)₃(AsW₉O₃₃)₂]^9/12- have been identified as the thermodynamic product that results from the conversion of the C_2v polyanion [(H₂O)(VO)₃(AsW₉O₃₃)₂]^9/12- through moderate heating. Conversely, the Sb^III-containing derivative gives exclusively the D_3h polyanion, probably either due to the extended lone pair of the trigonal Sb^III heterogroup that prevents the formation of the C_2v arrangement or the lability of the oxo-metalate bonds that favor chemical exchange. The electrochemical studies of sandwich-type polyoxometalates revealed that each {V═O} group gives rise to a one-electron transfer process. At last, the redox properties appear strongly altered in the 0.3-5 pH range, consistent with proton-coupled electron transfers.

Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PLpro

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has called for an urgent need for dedicated antiviral therapeutics. Metal complexes are commonly underrepresented in compound libraries that are used for screening in drug discovery campaigns, however, there is growing evidence for their role in medicinal chemistry. Based on previous results, we have selected more than 100 structurally diverse metal complexes for profiling as inhibitors of two relevant SARS-CoV-2 replication mechanisms, namely the interaction of the spike (S) protein with the ACE2 receptor and the papain-like protease PLpro . In addition to many well-established types of mononuclear experimental metallodrugs, the pool of compounds tested was extended to approved metal-based therapeutics such as silver sulfadiazine and thiomersal, as well as polyoxometalates (POMs). Among the mononuclear metal complexes, only a small number of active inhibitors of the S/ACE2 interaction was identified, with titanocene dichloride as the only strong inhibitor. However, among the gold and silver containing complexes many turned out to be very potent inhibitors of PLpro activity. Highly promising activity against both targets was noted for many POMs. Selected complexes were evaluated in antiviral SARS-CoV-2 assays confirming activity for gold complexes with N-heterocyclic carbene (NHC) or dithiocarbamato ligands, a silver NHC complex, titanocene dichloride as well as a POM compound. These studies might provide starting points for the design of metal-based SARS-CoV-2 antiviral agents.

Keggin-type polyoxometalate 1 : 1 complexes of Pb(II) and Bi(III): experimental, theoretical and luminescence studies

Bi3+ and Pb2+ uptake by a monolacunary Keggin-type [PW11O39]7- anion leads to the formation of [PW11O39Bi]4- and [PW11O39Pb]5- complexes with a stereochemically active lone pair at the incorporated heterometal. The two complexes were isolated as (TBA)4[PW11O39Bi] (1) and (TBA)5[PW11O39Pb] (2) and characterized by 31P and 183W NMR spectroscopy, high-resolution electrospray mass-spectrometry (HR-ESI-MS) and cyclic voltammetry (CV). EXAFS and XANES data confirm the unchanged oxidation state and ψ-square pyramidal geometry of Bi3+ and Pb2+ in 1 and 2. DFT calculations were used in order to (i) confirm the absence of ligands attached to the heterometal sites in both complexes and localize the lone pair, and (ii) assign all signals in the 183W NMR spectra. Complexes 1 and 2 demonstrate photoluminescence (PL). A reversible change in the PL spectra of both complexes in the presence of water vapor has been detected. On the contrary, PL data for sandwich-type ((CH3)4N)4K3[H4(PW11O39)2Bi]·25H2O (3) do not show sensitivity to water vapor.

Polyoxometalates in Biomedicine: Update and Overview

BACKGROUND

Polyoxometalates (POMs) are negatively charged metal-oxo clusters of early transition metal ions in high oxidation states (e.g., WVI, MoVI, VV). POMs are of interest in the fields of catalysis, electronics, magnetic materials and nanotechnology. Moreover, POMs were shown to exhibit biological activities in vitro and in vivo, such as antitumor, antimicrobial, and antidiabetic.

METHODS

The literature search for this peer-reviewed article was performed using PubMed and Scopus databases with the help of appropriate keywords.

RESULTS

This review gives a comprehensive overview of recent studies regarding biological activities of polyoxometalates, and their biomedical applications as promising anti-viral, anti-bacterial, anti-tumor, and anti-diabetic agents. Additionally, their putative mechanisms of action and molecular targets are particularly considered.

CONCLUSION

Although a wide range of biological activities of Polyoxometalates (POMs) has been reported, they are to the best of our knowledge not close to a clinical trial or a final application in the treatment of diabetes or infectious and malignant diseases. Accordingly, further studies should be directed towards determining the mechanism of POM biological actions, which would enable fine-tuning at the molecular level, and consequently efficient action towards biological targets and as low toxicity as possible. Furthermore, biomedical studies should be performed on solutionstable POMs employing physiological conditions and concentrations.

Effective inhibitory activity against MCF-7, A549 and HepG2 cancer cells by a phosphomolybdate based hybrid solid

A novel P₂Mo₅ cluster based hybrid solid [{4,4′-H₂bpy}{4,4′-Hbpy}₂{H₂P₂Mo₅O₂₃}]·5H₂O with effective anti-proliferation activity against MCF-7, HepG2 and A549 cancer cells comparable with a routinely used chemotherapeutic agent, methotrexate (MTX).

Synthesis, structural characterisation, and cytotoxicity studies of Bi, W, and Mo containing homo- and hetero-bimetallic polyoxometalates

Three new and different homo- and hetero-bimetallic polyoxometalate (POM) species have been synthesised by simple one-pot synthetic methods utilising naturally occurring bismite (Bi₂O₃) (or Bi(NO₃)₃·5H₂O) and aryl sulfonic acids. The POM species isolated are (NH₄)₁₄[Bi₂W₂₂O₇₆]·14H₂O (1·14H₂O), (NH₄)[Bi(DMSO)₇][Mo₈O₂₆]·H₂O (2·H₂O) and [(NH₄)₄(Mo₃₆O₁₀₈(OH)₄·16H₂O)]·45H₂O (3·45H₂O). The compounds have been characterised by X-ray crystallography, energy dispersive X-ray spectroscopy (EDX), powdered X-ray diffraction (PXRD), mass spectrometry (ESI-MS), Raman spectroscopy, thermogravimetric (TGA) and ICP analyis. In vitro cytoxicity and proliferation studies conducted on 1 and 3, highlight the low toxicity of these species.

Anti-zika virus activity of polyoxometalates

Zika virus (ZIKV) is an emerging infectious viral pathogen associated with severe fetal cerebral anomalies and the paralytic Guillain-Barrè syndrome in adults. It was the cause of a recent global health crisis following its entrance into a naïve population in the Americas. Nowadays, no vaccine or specific antiviral against ZIKV is available. In this study, we identified three polyoxometalates (POMs), the Anderson-Evans type [TeW₆O₂₄]^6- (TeW₆), and the Keggin-type [TiW₁₁CoO₄₀]^8-_ (TiW₁₁Co), and [Ti₂PW₁₀O₄₀]^7- (Ti₂PW₁₀), that inhibit ZIKV infection with EC₅₀s in the low micromolar range. Ti₂PW₁₀, the POM with the greatest selectivity index (SI), was selected and the step of ZIKV replicative cycle putatively inhibited was investigated by specific antiviral assays. We demonstrated that Ti₂PW₁₀ targets the entry process of ZIKV infection and it is able to significantly reduce ZIKV progeny production. These results suggest that the polyanion Ti₂PW₁₀ could be a good starting point to develop an effective therapeutic to treat ZIKV infection.

Two rare Cr–Ln (Ln = Dy, Tb) heterometallic cluster substituted polyoxometalates featuring hexameric aggregates: hydrothermal syntheses, crystal structures and magnetic studies

Two hexameric Cr–Ln cluster substituted POMs have been obtained under hydrothermal conditions. They represent the first examples of 3d–4f heterometallic cluster substituted POMs incorporating Cr–Ln clusters.

Synthesis and Antibacterial Activity of Polyoxometalates with Different Structures

A new inorganic-organic hybrid compound, [{Cu(phen)2}2(H4W12O40)], was synthesized, and its crystal structure was determined. The Keggin anion H4W12O40 4- was grafted with two coordination units {Cu(phen)2}, forming an electrically neutral molecule. The antibacterial activity of several polyoxometalate compounds with different anionic structures including the new compound was studied. The results show that the compound 1 can inhibit the growth of Enterococcus faecalis FA2 strains and that antibacterial activity of the polyoxometalate compounds is dependent with component elements of POM but is less relative with the anion structures.

The antibacterial activity of polyoxometalates: structures, antibiotic effects and future perspectives

Polyoxometalates (POMs) are, mostly anionic, metal oxide compounds that span a wide range of tunable physical and chemical features rendering them very interesting for biological purposes, an continuously emerging but little explored field. Due to their biological and biochemical effects, including antitumor, -viral and -bacterial properties, POMs and POM-based systems are considered as promising future metallodrugs. In this article, we focus on the antibacterial activity of POMs and their therapeutic potential in the battle against bacteria and their increasing resistance against pharmaceuticals. Recent advances in the synthesis of POMs are highlighted, with emphasis on the development and properties of biologically active POM-based hybrid and nanocomposite structures. By analysing the antibacterial activity and structure of POMs, putative mode of actions are provided, including potential targets for POM-protein interactions, and a structure-activity-relationship was established for a series of POMs against two bacteria, namely Helicobacter pylori and Streptococcus pneumoniae.

Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results

We synthesized a series of polyoxometalate-bisphosphonate complexes containing MoVIO6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and 31P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ∼5 μM per bisphosphonate ligand. The effects of bisphosphonate complexation on IC50 decreased with increasing bisphosphonate chain length: C0 ≈ 6.1×, C6 ≈ 3.4×, and C8 ≈ 1.1×. We then determined the activity of one of the most potent compounds in the series, Mo4Zol2Mn(III), against SK-ES-1 sarcoma cells in a mouse xenograft system finding a ∼5× decrease in tumor volume than found with the parent compound zoledronate at the same compound dosing (5 μg/mouse). Overall, the results are of interest since we show for the first time that heteropolyoxomolybdate-bisphosphonate hybrids kill tumor cells in vitro and significantly decrease tumor growth, in vivo, opening up new possibilities for targeting both Ras as well as epidermal growth factor receptor driven cancers.